Similar articles

• Dopamine-modulating drugs, amenorrhea-galactorrhea and neuropsychiatric illnesses.

  Frye PE. Frye PE. W V Med J. 1983 Aug;79(8):161-4. W V Med J. 1983. PMID: 6138902 No abstract available.
• Management of psychotic symptoms associated with the disease and its treatments.

  Monias A, Samuels SC. Monias A, et al. Geriatrics. 2001 Nov;56(11):56-7. Geriatrics. 2001. PMID: 11710816 No abstract available.
• Role of dopamine receptors in neurological drug treatment.

  Rinne UK. Rinne UK. Ann Clin Res. 1988;20(5):334-9. Ann Clin Res. 1988. PMID: 3218905 No abstract available.
• The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes.

  Goldstein M, Lieberman AN, Takasugi N, Shimizu Y, Kuga S. Goldstein M, et al. Adv Neurol. 1990;53:101-6. Adv Neurol. 1990. PMID: 1978511 Review. No abstract available.
• Psychosis in Parkinson's disease: case studies.

  Salter BC, Anderson KE, Weiner WJ. Salter BC, et al. Neurol Clin. 2006 May;24(2):363-9. doi: 10.1016/j.ncl.2006.01.003. Neurol Clin. 2006. PMID: 16684637 Review.